CHMA Chiasma Inc.

0  0%
Previous Close 7.99
Price To Book 9.74
Market Cap 253,825,641
Shares 31,767,915
Volume 5
Short Ratio
Av. Daily Volume 209,241

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 3Q 2019.
Mycapssa - OPTIMAL
CRL April 15 2016
Phase 3 data due 2H 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

Latest News

  1. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  2. Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®
  3. Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%
  4. Will Chiasma to Surge Higher?
  5. Edited Transcript of CHMA earnings conference call or presentation 9-May-19 9:00pm GMT
  6. Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement
  7. Chiasma: 1Q Earnings Snapshot
  8. Chiasma Reports First Quarter 2019 Results
  9. Chiasma to Report First Quarter Financial Results on May 9, 2019
  10. Shareholders Are Raving About How The Chiasma (NASDAQ:CHMA) Share Price Increased 312%
  11. Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option
  12. Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock
  13. 5 Stocks Moving In Thursday's After-Hours Session
  14. Chiasma Announces Proposed Offering of Common Stock
  15. Chiasma Announces Three Poster Presentations at ENDO 2019
  16. Chiasma Reports Fourth Quarter and Year End 2018 Results
  17. Chiasma to Participate in Three Investor Conferences in March
  18. Chiasma Announces Support for Rare Disease Day 2019
  19. Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?
  20. Chiasma Previews Important Upcoming Milestones